Minoryx Therapeutics

Minoryx pockets €51M to guide rare disease drug to market

Minoryx has persuaded investors to overlook its phase 2/3 failure, and it pulled in 51 million euros to support a push to bring the drug to market.

Nick Paul Taylor May 31, 2022 10:00am

Roche-backed Minoryx raises €21M to expand CNS R&D

Sep 26, 2018 8:50am

EuroBiotech: More Articles of Note

Feb 22, 2018 10:00am

Novartis, Sanofi-backed NeuroVia closes $14M series A

Jul 20, 2017 7:30am